The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent

Protein Expression and Purification

Volumn 48, Issue 1, 2006, Pages 61-68

  Kirschner, Marc ^a,b   Monrose, Val ^b   Paluch, Maciej ^b   Techodamrongsin, Nipa ^a   Rethwilm, Axel ^a   Moore, John P ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Expression; Linear polyethylenimine; Pseudovirus production; Transient transfection; Trimeric HIV 1 envelope vaccine antigens

Indexed keywords

GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HIV 1 ENVELOPE PROTEIN GP140; HIV-1 ENVELOPE PROTEIN GP140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POLYETHYLENEIMINE; VIRUS ENVELOPE PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CHO CELL; CRICETULUS; GENETIC TRANSFECTION; GENETICS; HAMSTER; HELA CELL; HUMAN; IMMUNOLOGY; METHODOLOGY; PLASMID;

AIDS VACCINES; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, ENV; HELA CELLS; HUMANS; PLASMIDS; POLYETHYLENEIMINE; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646867165     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.02.017     Document Type: Article

References (25)

1. Moulard M., and Decroly E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochem. Biophys. Acta 1469 (2000) 121-132
2. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 (2003) 36-50
3. The rgp120 HIV Vaccine Study Group, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection, J. Infect. Dis. 191 (2005) 654-665.
4. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis Gurwith D.P., Heyward M., Jobes W.L., Popovic D.V., Self V., Sinangil S.G., Burke F., Berman D., and Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191 (2005) 666-677
5. Markel H. The search for effective HIV vaccines. N. Engl. J. Med. 353 (2005) 753-757
6. Cohen J. AIDS vaccine trial produces disappointment and confusion. Science 299 (2003) 1290-1291
7. Connor R.I., Korber B.T.M., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kunstman K.J., McDonald D., McWilliams N., Trkola A., Moore J.P., and Wolinsky S.M. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72 (1998) 1552-1576
8. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
9. Schülke N., Vesanen M.S., Sanders R.W., Zhu P., Lu M., Anselma D.J., Villa A.R., Parren P.W., Binley J.M., Roux K.H., Maddon P.J., Moore J.P., and Olson W.C. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol. 76 (2002) 7760-7776
10. Binley J.M., Sanders R.W., Clas B., Schülke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 (2000) 627-643
11. Sanders R.W., Vesanen M., Schülke N., Master A., Schiffner L., Kalyanaraman R., Paluch M., Berkhout B., Maddon P.J., Olson W.C., Lu M., and Moore J.P. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76 (2002) 8875-8889
12. Binley J.M., Sanders R.W., Master A., Cayanan C.S., Wiley C.L., Schiffner L., Travis B., Kuhmann S., Burton D.R., Hu S.L., Olson W.C., and Moore J.P. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76 (2002) 2606-2616
13. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., and Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92 (1995) 7297-7301
14. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6 (1996) 315-324
15. Abacioglu Y.H., Fouts T.R., Laman J.D., Claassen E., Pincus S.H., Moore J.P., Roby C.A., Kamin-Lewis R., and Lewis G.K. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res. Hum. Retroviruses 10 (1994) 371-381
16. Leurs C., Jansen M., Pollok K.E., Heinklein M., Schmidt M., Wissler M., Lindemann D., Von Kalle C., Rethwilm A., Williams D.A., and Hanenberg H. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum. Gene Ther. 14 (2003) 509-519
17. Beddows S., Schülke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., and Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79 (2005) 8812-8827
18. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 (2005) 1252-1261
19. Pietschmann T., Heinkelein M., Heldmann M., Zentgraf H., Rethwilm A., and Lindemann D. Foamy virus capsids require the cognate envelope protein for particle export. J. Virol. 73 (1999) 2613-2621
20. Jármy G., Heinkelein M., Weissbrich B., Jassoy C., and Rethwilm A. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J. Med. Virol. 64 (2001) 223-231
21. Herrera C., Klasse P.J., Michael E., Kake S., Barnes K., Kibler C.W., Campbell-Gardener L., Si Z., Sodroski J., Moore J.P., and Beddows S. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 20 (2005) 154-172
22. Gao X., Wang H., and Sairenji T. Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. J. Virol. 78 (2004) 11798-11806
23. Louder M.K., Sambor A., Chertova E., Hunte T., Barrett S., Ojong F., Sanders-Buell E., Zolla-Pazner S., McCutchan F.E., Roser J.D., Gabuzda D., Lifson J.D., and Mascola J.R. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339 (2005) 226-238
24. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79 (2005) 10103-10107
25. Derouazi M., Girard P., Van Tilborgh F., Iglesias K., Muller N., Bertschinger M., and Wurm F.M. Serum-free large-scale transient transfection of CHO cells. Biotechnol. Bioeng. 87 (2004) 537-545